Lilly Asia Ventures led the Sinopharm-backed oncology, immunity and inflammation therapeutics startup’s series B round, which included Legend Capital.

China-based cancer therapy developer Lynk Pharmaceuticals received $50m today in a series B round led by Lilly Asia Ventures (LAV), a corporate venturing subsidiary of pharmaceutical firm Eli Lilly.

Legend Capital – a venture capital firm spun off by conglomerate Legend Holdings – also took part in the round, as did Hangzhou Heda Biological Medicine Venture Capital Partnership, Med-Fine Capital and New Alliance Capital.

Founded in 2018, Lynk is developing small molecule drugs to treat various types of autoimmune and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn